Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Equity Ratio (2016 - 2025)

Historic Equity Ratio for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 0.32.

  • NovaBay Pharmaceuticals' Equity Ratio rose 1502.19% to 0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32, marking a year-over-year increase of 1502.19%. This contributed to the annual value of 0.04 for FY2024, which is 11027.33% down from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Equity Ratio stood at 0.32, which was up 1502.19% from 0.61 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Equity Ratio high stood at 0.82 for Q2 2021, and its period low was 0.16 during Q2 2024.
  • Its 5-year average for Equity Ratio is 0.49, with a median of 0.6 in 2023.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Equity Ratio surged by 221894.14% in 2021 and then tumbled by 12938.71% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Equity Ratio (Quarter) stood at 0.42 in 2021, then soared by 51.72% to 0.64 in 2022, then tumbled by 43.0% to 0.37 in 2023, then tumbled by 110.27% to 0.04 in 2024, then soared by 943.91% to 0.32 in 2025.
  • Its last three reported values are 0.32 in Q3 2025, 0.61 for Q2 2025, and 0.62 during Q1 2025.